Yes, there is a clinically significant drug interaction between Qelbree (viloxazine) and fluoxetine that requires careful consideration.
Qelbree is a moderate CYP1A2 inhibitor, while fluoxetine is primarily metabolized by CYP2D6 and is itself a potent CYP2D6 inhibitor—the interaction risk is bidirectional but primarily concerns co-administration of Qelbree with other CYP1A2-sensitive substrates rather than fluoxetine specifically. However, the combination warrants caution due to overlapping serotonergic effects and the potential for additive side effects.
Primary Interaction Mechanism
The FDA label for Qelbree explicitly states that coadministration with moderate sensitive CYP1A2 substrates is not recommended, and dose reduction may be warranted 1. Viloxazine functions as a CYP1A2 inhibitor 2, which means it can increase plasma concentrations of drugs metabolized through this pathway.
Fluoxetine is NOT primarily metabolized by CYP1A2—it is metabolized through CYP2D6 3. Therefore, the direct pharmacokinetic interaction via CYP1A2 inhibition is minimal. However, fluoxetine itself is a potent CYP2D6 inhibitor and can dramatically increase levels of drugs metabolized by this enzyme (2-11 fold increases documented with tricyclics) 4.
Key Clinical Considerations
Viloxazine's Metabolic Profile
- Viloxazine undergoes 5-hydroxylation via CYP2D6 as a minor pathway in humans 2
- The estimated difference between poor metabolizers and extensive metabolizers is <2-fold, suggesting CYP2D6 inhibition by fluoxetine would have limited clinical impact on viloxazine levels 2
- The major metabolic route is 5-hydroxylation followed by glucuronidation 2
Pharmacodynamic Concerns
The more significant concern is pharmacodynamic rather than pharmacokinetic:
- Serotonergic effects: Viloxazine has serotonergic activity (5-HT2C agonism and 5-HT2B antagonism) 5, and fluoxetine is a selective serotonin reuptake inhibitor 3
- Additive CNS effects: Both medications can cause somnolence, and viloxazine commonly causes sleepiness and tiredness 1
- Suicidality monitoring: Both carry black box warnings for treatment-emergent suicidality, particularly in adolescents and young adults 3, 1
Common Pitfalls to Avoid
Do not assume this is a contraindication: Unlike MAOIs (which are absolutely contraindicated with Qelbree 1), fluoxetine can potentially be used with viloxazine with appropriate monitoring
Monitor for excessive sedation: The combination may produce additive CNS depression—counsel patients about driving and operating machinery 1
Watch for cardiovascular effects: Both medications can affect blood pressure and heart rate; baseline and ongoing monitoring is essential 1
Screen for bipolar disorder: Both medications can precipitate manic episodes in susceptible individuals 3, 1
Clinical Recommendation Algorithm
If considering this combination:
- Start with lower doses of viloxazine when fluoxetine is already on board
- Monitor closely for excessive somnolence, sedation, or fatigue
- Check blood pressure and heart rate at baseline and during titration 1
- Assess for mood destabilization or emergence of manic symptoms
- Screen for suicidal ideation, especially in the first few months or with dose changes 1
- Consider the clinical necessity—if ADHD symptoms are the primary target and depression is well-controlled on fluoxetine, the combination may be reasonable with monitoring
The interaction is manageable but not negligible—the primary concern is additive side effects rather than dangerous pharmacokinetic interactions. This differs substantially from the absolute contraindication with MAOIs or the "not recommended" status for CYP1A2 substrates like duloxetine, tizanidine, or theophylline 1.